Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 0 | 0 | 0 | 0 | 10,006 |
| Gross Profit | N/A | N/A | N/A | N/A | 10,006 |
| Operating Expenses | 50,040 | 31,109 | 28,239 | 27,816 | 24,161 |
| Operating Income | -50,040 | -31,109 | -28,239 | -27,816 | -14,155 |
| Interest Expense | 158 | 604 | 688 | 855 | 1,808 |
| Other Income | 3,841 | 1,677 | 605 | 864 | 233 |
| Pre-tax Income | -46,357 | -30,036 | -28,322 | -27,807 | -15,730 |
| Income Tax | 1 | 1 | 1 | 1 | N/A |
| Net Income Continuous | -46,358 | -30,037 | -28,323 | -27,808 | -15,730 |
| Net Income | $-46,358 | $-30,037 | $-28,323 | $-27,808 | $-15,730 |
| EPS Basic Total Ops | -0.82 | -1.58 | -1.86 | -3.24 | -4.50 |
| EPS Basic Continuous Ops | -0.82 | -1.58 | -1.86 | -3.24 | -4.50 |
| EPS Diluted Total Ops | -0.82 | -1.58 | -1.86 | -3.24 | -4.50 |
| EPS Diluted Continuous Ops | -0.82 | -1.58 | -1.86 | -3.24 | -4.50 |
| EPS Diluted Before Non-Recurring Items | -0.82 | -1.58 | -1.86 | -3.20 | -4.50 |
| EBITDA(a) | $-51,250 | $-31,039 | $-28,302 | $-27,357 | $-13,688 |